Charles Schneider

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib”.

The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1467

N/A

0.873DataRank · unranked

24 citations

Arielle Yablonovitch, Jacob E. Till, Jennifer Yen, Lesli A. Kiedrowski, Ryan Hood +9 more

Quantifying the impact of the COVID-19 pandemic on gastrointestinal cancer care delivery.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.30

N/A

0DataRank · unranked

13 citations

Casey Kim, Chris Boedec, Charles Schneider, Ursina Teitelbaum, Edgar Ben‐Josef +5 more

A descriptive study on the treatment and outcomes of patients with platinum-sensitive, advanced, BRCA- or PALB2-related pancreatic cancer who have progressed on rucaparib.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4131

N/A

0DataRank · unranked

2 citations

Mark H. O’Hara, Ursina Teitelbaum, Thomas B. Karasic, Charles Schneider, Natallia Izgur +4 more